ReviewCancers2021
Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Pooled it
- Nutrigenomics and Epigenetic Regulation in Cancer Prevention: Molecular Mechanisms, Dietary Bioactives, and Translational Perspectives.Nutrients · 2026Review
- "Immune senescence and dormant tumor cells: reconceptualizing breast cancer recurrence as an affliction of aging and chronic inflammation".Annals of medicine and surgery (2012) · 2026Review
- The role of liquid biopsy in the molecular characterization of HPV-related cancers.Folia microbiologica · 2026Review
- Multimodal modeling based on DNA methylation analysis in bronchoalveolar lavage fluid for early lung cancer detection.Scientific reports · 2026Article
- Research progress on long non‑coding RNAs in lung cancer (Review).Molecular medicine reports · 2026Review
- Emergence of Liquid Biopsy in Precision Oncology: A Review of its diagnostic, Predictive and Therapeutic Applications in Gallbladder Cancer.Journal of gastrointestinal cancer · 2026Review
- The Great Potential of DNA Methylation in Triple-Negative Breast Cancer: From Biological Basics to Clinical Application.Biomedicines · 2026Review
- Associations Between Non-Genetic Risk Factors and DNA Methylation Alterations in Barrett's Esophagus and Its Progression to Esophageal Adenocarcinoma.International journal of molecular sciences · 2025Review
- Structure-informed models for ionic current prediction in nanopore sequencing of expanded dna alphabets.Nucleic acids research · 2025Article
- Minimal Residual Disease Detection in Peripheral Blood of Patients With High-Risk Neuroblastoma Correlates With Outcome in the International GPOH-DCOG Prospective Validation Study.JCO precision oncology · 2025Article
- Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium.Neuro-oncology · 2025Review
- Liquid biopsy in breast cancer: Redefining precision medicine.The journal of liquid biopsy · 2025Review
- Transforming Cancer Diagnostics: The Emergence of Liquid Biopsy and Epigenetic Markers.MedComm · 2025Review
- Shining the Path of Precision Diagnostic: Advancements in Photonic Sensors for Liquid Biopsy.Biosensors · 2025Review
- Liquid Biopsy-Based DNA Methylation Biomarkers for Precision Medicine in Breast Cancer.Expert reviews in molecular medicine · 2025Review
- Artificial Intelligence in cancer epigenomics: a review on advances in pan-cancer detection and precision medicine.Epigenetics & chromatin · 2025Review
- Acidity and hypoxia of tumor microenvironment, a positive interplay in extracellular vesicle release by tumor cells.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- DNA Methylation in Lung Cancer: Predictive Biomarkers for Effective Immunotherapy.International journal of general medicine · 2025Review
- [A two-site combined prediction model based on HOXA9 DNA methylation for early screening of risks of meningioma progression].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early alterations in cancer include the deregulation of epigenetic events such as changes in DNA methylation and abnormal levels of non-coding (nc)RNAs. Although these changes can be identified in tumors, alternative sources of samples may offer advantages over tissue biopsies. Because tumors shed DNA, RNA, and proteins, biological fluids containing these molecules can accurately reflect alterations found in cancer cells, not only coming from the primary tumor, but also from metastasis and from the tumor microenvironment (TME). Depending on the type of cancer, biological fluids encompass blood, urine, cerebrospinal fluid, and saliva, among others. Such samples are named with the general term "liquid biopsy" (LB). With the advent of ultrasensitive technologies during the last decade, the identification of actionable genetic alterations (i.e., mutations) in LB is a common practice to decide whether or not targeted therapy should be applied. Likewise, the analysis of global or specific epigenetic alterations may also be important as biomarkers for diagnosis, prognosis, and even for cancer drug response. Several commercial kits that assess the DNA promoter methylation of single genes or gene sets are available, with some of them being tested as biomarkers for diagnosis in clinical trials. From the tumors with highest incidence, we can stress the relevance of DNA methylation changes in the following genes found in LB:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.